TY - JOUR
T1 - Hyperammonemia syndrome associated with Ureaplasma spp. Infections in immunocompromised patients and transplant recipients
T2 - A systematic review and meta-analysis
AU - Tantengco, Ourlad Alzeus G.
AU - De Jesus, Federico Cristobal C.
AU - Gampoy, Eloina Faye S.
AU - Ornos, Eric David B.
AU - Vidal, Manuel S.
AU - Abad, Cybele Lara R.
N1 - Publisher Copyright:
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2021/7
Y1 - 2021/7
N2 - Background: Hyperammonemia syndrome (HS) is reported to occur in patients with Ureaplasma spp. infections. We performed a systematic review and meta-analysis of studies reporting HS in patients with Ureaplasma spp. infection. Methods: We searched several databases (CINAHL, OVID, ProQuest, and Scopus) from inception to January 2021. We described case reports and series, and performed a meta-analysis for all cohort studies. The pooled risk ratio (RR) for the association between HS and Ureaplasma spp. infections was derived using a random-effects model. Results: The systematic review yielded 18 studies. HS was reported in 53 patients with Ureaplasma spp. infections. The most common clinical manifestations were neurologic. Meta-analysis showed a higher incidence of HS (41.67%) and peak ammonia concentration among Ureaplasma spp.–infected lung transplant recipients compared with Ureaplasma spp.–negative recipients (2.84%). The risk of HS was significantly increased in Ureaplasma spp.–infected recipients compared with Ureaplasma spp.–negative recipients (RR: 14.64; CI: 2.85–75.24). Mortality from Ureaplasma-associated HS was 27.27% compared with 5.24% in those with HS from other causes. Conclusions: The risk of developing HS is higher among Ureaplasma-infected patients compared with uninfected patients. Lung transplant recipients appear to be disproportionally affected, and HS should be suspected in those who present with neurologic symptoms.
AB - Background: Hyperammonemia syndrome (HS) is reported to occur in patients with Ureaplasma spp. infections. We performed a systematic review and meta-analysis of studies reporting HS in patients with Ureaplasma spp. infection. Methods: We searched several databases (CINAHL, OVID, ProQuest, and Scopus) from inception to January 2021. We described case reports and series, and performed a meta-analysis for all cohort studies. The pooled risk ratio (RR) for the association between HS and Ureaplasma spp. infections was derived using a random-effects model. Results: The systematic review yielded 18 studies. HS was reported in 53 patients with Ureaplasma spp. infections. The most common clinical manifestations were neurologic. Meta-analysis showed a higher incidence of HS (41.67%) and peak ammonia concentration among Ureaplasma spp.–infected lung transplant recipients compared with Ureaplasma spp.–negative recipients (2.84%). The risk of HS was significantly increased in Ureaplasma spp.–infected recipients compared with Ureaplasma spp.–negative recipients (RR: 14.64; CI: 2.85–75.24). Mortality from Ureaplasma-associated HS was 27.27% compared with 5.24% in those with HS from other causes. Conclusions: The risk of developing HS is higher among Ureaplasma-infected patients compared with uninfected patients. Lung transplant recipients appear to be disproportionally affected, and HS should be suspected in those who present with neurologic symptoms.
KW - hyperammonemia syndrome
KW - immunocompromised
KW - transplantation
KW - Ureaplasma infection
UR - https://www.scopus.com/pages/publications/85106223553
UR - https://www.scopus.com/pages/publications/85106223553#tab=citedBy
U2 - 10.1111/ctr.14334
DO - 10.1111/ctr.14334
M3 - Article
C2 - 33948993
AN - SCOPUS:85106223553
SN - 0902-0063
VL - 35
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 7
M1 - e14334
ER -